SMOC and HY-IPT Establish Strategic Partnership to Advance Precision Medicine Research

Southern Model Organisms (SMOC) has officially signed a Memorandum of Understanding on Industry-University-Research Strategic Cooperation with the Hanyang Institute for Personalized Therapeutics of Hanyang University (HY-IPT). Leveraging their respective strengths in model organism R&D and research infrastructure, the two parties will advance in-depth cooperation in joint R&D, talent exchanges, and national-level research project collaboration. Together, they aim to build an industry-university-research collaborative system, nurture outstanding talent, and drive innovation and development in life science research.

At the signing ceremony, Professor Dong-Tak Jung of HY-IPT stated: "Reaching this strategic partnership with SMOC is of great significance to us. SMOC possesses formidable strength in genetically modified animal models and preclinical CRO services, which serves as a crucial foundation for HY-IPT to carry out and advance research in personalized therapy and translational medicine. We look forward to relying on SMOC’s high-quality laboratory animal resources and R&D platform, combined with HY-IPT's long-term accumulation and expertise in the life sciences, to jointly tackle multiple research projects and cultivate talent, and to build a long-term, stable, mutually beneficial and win-win cooperative relationship."

Dr. Jian Fei, Chairman of SMOC, said: "We are very pleased to have reached a strategic partnership with HY-IPT. SMOC has been deeply engaged in the field of model animals for more than two decades, establishing a technical platform centered on genetically modified animal-model R&D, laboratory-animal breeding, and CRO services; HY-IPT, meanwhile, possesses an advanced and comprehensive research system and an international research perspective in personalized therapy and the life sciences. We believe that through the open sharing of both parties' laboratories, equipment, and data, we will effectively accelerate the processes of drug discovery and clinical translation, and together contribute to global life-science and biomedical innovation."

The signing of this MOU marks a further expansion of SMOC's international industry-university-research cooperation footprint. The two parties will continue to advance the deep integration of industry, university, and research, connecting the entire chain from basic research and technology development to industrial translation. Together, they will build a long-term collaborative innovation mechanism, empower frontier life-science exploration and innovative drug R&D, and help build an open and interconnected international biomedical innovation ecosystem.

About HY-IPT

The Hanyang Institute for Personalized Therapeutics is affiliated with the ERICA Campus of Hanyang University in Korea. Relying on the strengths of disciplines such as the Department of Molecular Life Sciences, HY-IPT focuses on personalized therapy, precision medicine, and translational medicine research, making it one of the most scientifically influential research platforms in these fields in Korea.

About SMOC

Southern Model Organisms is a national high-tech enterprise dedicated to animal-model R&D and technical services. Adhering to its mission of "Editing Genes, Decoding Life," the company has devoted twenty-six years to the field of model organisms and built a globally leading, largest-scale standardized mouse and rat model resource library. It currently possesses more than 18,000 animal models with independent intellectual property rights, covering tens of thousands of gene-knockout/conditional-knockout mice, more than 700 Cre or fluorescent reporter tool mice, more than 1,500 target humanized models, hundreds of complex-disease models, as well as NMG severe immunodeficient mice and SmocMab fully human antibody mice, among others. Headquartered in Shanghai, Model Organisms has branch offices in Beijing, Guangdong, and Texas, forming a globally radiating R&D and operations network. SMOC is committed to providing global customers with one-stop, full-process solutions ranging from model customization, breeding, and phenotyping analysis to preclinical CRO services. Looking to the future, Model Organisms will continue to leverage its model organism capabilities to accelerate life-science innovation and the drug-R&D process.